IPDX DIAGNOSTICS OU

Their core work

IPDX Diagnostics is a small Estonian biotech company focused on developing molecular diagnostic tests for difficult-to-diagnose conditions. Their commercial work centers on point-of-care diagnostics — rapid, clinician-facing tests that can replace slow and costly laboratory workflows. IBDetect, their coordinated SME Phase 1 project, targeted differential diagnosis of inflammatory bowel disease, a market need driven by the clinical challenge of distinguishing Crohn's disease from ulcerative colitis. Their more recent role in the TRENDO consortium expands their footprint into reproductive medicine, where they contribute to translational research on endometriosis using microRNA biomarkers, adult stem cells, and proteoglycan analysis.

What they specialise in

How they've shifted over time

Their H2020 entry in 2019 was product-driven: IBDetect was a commercial feasibility project aimed at bringing an IBD diagnostic test to market through the SME Instrument. No research keywords were recorded for that project, consistent with a technology development rather than basic science focus. By 2021, their participation in TRENDO represents a clear pivot toward academic-style translational research, with a rich keyword profile spanning endometriosis, microRNA, adult stem cells, and proteoglycans — suggesting they are building a scientific evidence base in reproductive medicine, likely to support future diagnostic product development in that space.

IPDX appears to be systematically moving into underdiagnosed, high-unmet-need conditions — first IBD, now endometriosis — suggesting a pipeline strategy built around diseases where better diagnostics have clear commercial value and clinical demand.

How they like to work

IPDX has demonstrated both project leadership (coordinator on IBDetect) and junior partnership roles (participant in TRENDO), indicating they can adapt to different positions in a consortium depending on the project type. With only 8 unique partners across 7 countries from 2 projects, they work in compact international teams rather than large multi-partner networks. Their coordinator experience, despite being a micro-SME, suggests an entrepreneurial posture and willingness to take ownership of project deliverables.

IPDX has connected with 8 unique partners across 7 countries — a broad geographic spread for an organization with only 2 projects, reflecting the international composition of both the MSCA-RISE scheme and the SME Instrument consortia. No recurring partner relationships can be identified from this data set.

What sets them apart

IPDX sits at the intersection of diagnostics product development and translational biomedical research, which is an uncommon combination for a micro-SME. Most diagnostics companies at this scale either focus purely on commercialization or purely on science — IPDX appears to be doing both in sequence, using research consortia to build the evidence base for future products. Their focus on conditions defined by diagnostic delay (IBD, endometriosis) positions them in markets where a validated PoC test would have immediate clinical and commercial uptake, giving potential partners a clear path from research to revenue.

Highlights from their portfolio

• IBDetect
  Coordinator role on a competitive SME Phase 1 grant — IPDX led this project independently, demonstrating they can manage EU-funded product development rather than just participate in academic research.
• TRENDO
  Participation in an MSCA-RISE network on endometriosis places them inside a multi-country translational research programme with a rich molecular keyword profile, suggesting meaningful scientific contribution beyond a token industry role.